EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates

Peggy Lu, Francesco Alletto, Bosul Lee, Elizabeth Burk, Jasmine Martinez, Fabio Prati, Emilia Caselli iD, Brad Spellberg, Brian Luna iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0287102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Peggy Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America. Hauptthemen laut MEDLINE: Rifamycins, Acinetobacter baumannii. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, we reported rifabutin hyper-activity against Acinetobacter baumannii . We sought to characterize if any additional rifamycins (n = 22) would also display hyper-activity when tested in iron-limited media against A . baumannii , K . pneumoniae , and E . coli . MICs were determined against representative clinical isolates using the iron-limited media RPMI-1640. Only rifabutin was hyperactive against A . baumannii .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifamycinsAcinetobacter baumanniiEscherichia coliKlebsiella pneumoniaeRifabutinIronMicrobial Sensitivity Tests

Substanzen

RifamycinsRifabutinIron

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, United States of America.
  • Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy.
  • Los Angeles General Medical Center, Los Angeles, California, United States of America.

ORCID-Profile: Emilia Caselli, Brian Luna

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lu, P., Alletto, F., Lee, B., Burk, E., Martinez, J., Prati, F., Caselli, E., Spellberg, B., & Luna, B. (2023). Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates. PLOS ONE. https://doi.org/10.1371/journal.pone.0287102

Vancouver

Lu P, Alletto F, Lee B, Burk E, Martinez J, Prati F, et al. Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates. PLOS ONE. 2023. doi:10.1371/journal.pone.0287102

BibTeX
@article{Lu2023,
  author = {Lu, Peggy and Alletto, Francesco and Lee, Bosul and Burk, Elizabeth and Martinez, Jasmine and Prati, Fabio and Caselli, Emilia and Spellberg, Brad and Luna, Brian},
  title = {Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0287102}
}
Kostenlos starten →